Selected Publications


     

    Genomics

  1. Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice.
    Huang, S. et al. Genome Biol. 2005;6(10):R84.
  2. Three microarray platforms: an analysis of their concordance in profiling gene expression.
    Peterson, D. et al. BMC Genomics, 6:63, 2005.
  3. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN-mediated apoptotic response specific to the rat ventral prostate.
    Desai, K.V. et al. Mol Endocrinology, 18(12):2895-907, 2004.
  4. Global Expression Profiling Identifies Potential Metastasis Modifier Genes in MMTV-PyMT Transgenic Mice: correlation to human disease.
    Qiu, T-H. et al. Cancer Research, 64:5973-81, 2004.
  5. Effects of pooling mRNA in microarray class comparisons.
    Shih, J.H. et al. Bioinformatics 20(18):3318-25., 2004.
  6. Gene Expression Profiling Identifies IL-13 receptor alpha2 chain as a therapeutic target in prostate tumor cells over-expressing adrenomedullin.
    Gonzalez-Moreno, O. et al. Int. J. Cancer 114(6):870-8, 2005.
  7. Molecular differentiation of high and moderate grade human prostate cancer by cDNA microarray analysis.
    Best, C. et al. Diagnostic Molecular Pathology, 12(2):63-70, 2003.
  8. Alterations in Gene Expression Profiles During Prostate Cancer Progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
    Calvo, A. et al. Cancer Research, 62:5325-5335, 2002
  9. Initiating oncogenic event determines gene-expression patterns of human breast cancer models.
    Desai, KV et al. Proc.Natl.Acad.Sci.U.S.A, 99(10):6967-6972, 2002.
  10. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice.
    Liu, ML et al. Oncogene, 20(16):2044-2049, 2001.
  11. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice.
    Liu, ML et al. Oncogene, 17(18):2403-2411, 1998.

    12. Models

    Mammary

  12. Reduced circulating IGF-I levels delays the onset of chemically- and genetically-induced mammary tumors.
    Wu, Y. et al. Cancer Research, 63(15):4384-8, 2003.
  13. Development and characterization of a progressive series of hormone-responsive mammary adenocarcinomas cell lines derived from the C3(1)/SV40 large T-antigen transgenic mouse model.
    Holzer, R.G. et al. Breast Cancer Research and Prevention, 77(1):65-76, 2003.
  14. Adipose tissue: A vital in vivo role in mammary gland development but not differentiation.
    Couldrey, C et al. Dev.Dyn., 223(4):459-468, 2002.
  15. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage.
    Shibata, MA et al. EMBO J., 18(10):2692-2701, 1999.
  16. Estrogen promotes mammary tumor development in C3(1)/SV40 large T- antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
    Yoshidome, K et al. Cancer Res., 60(24):6901-6910, 2000.
  17. P53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
    Shibata, MA et al. Cancer Res., 56(13):2998-3003, 1996.
  18. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
    Maroulakou, IG et al. Proc.Natl.Acad.Sci.U.S.A, 91(23):11236-11240, 1994.

    19. Prostate

  19. Disruption of Growth Hormone Signaling Retards Early Stages of Prostate Carcinogenesis in the C3(1)/Tag Mouse.
    Wang, Z. et al. Endocrinology, 146(12):5188-96, 2005.
  20. Luciferase Transgenic Mouse Model: visualization of prostate development and its androgen responsiveness in live animals.
    Hsieh, C-L. et al. J Mol Endocrinol, 35(2):293-304, 2005.
  21. Prostate Development and Carcinogenesis in Prolactin Receptor Kockout Mice.
    Robertson, F.G. et al. Endocrinology, 144(7):3196-205, 2003.
  22. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.
    Soares, CR et al. Neoplasia., 4(2):112-120, 2002.
  23. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
    Shibata, MA et al. Cancer Res., 56(21):4894-4903, 1996.
  24. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
    Maroulakou, IG et al. Proc.Natl.Acad.Sci.U.S.A, 91(23):11236-11240, 1994.

    25. Other

  25. Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP- 2 expression.
    Maroulakou, IG et al. Oncogene, 18(39):5435-5447, 1999.
  26. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice.
    Hahm, KB et al. Aliment.Pharmacol.Ther., 16 Suppl 2:115-27.:115-127, 2002.
  27. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease.
    Hahm, KB et al. Gut, 49(2):190-198, 2001.
  28. Loss of TGF-beta signaling contributes to autoimmune pancreatitis.
    Hahm, KB et al. J.Clin.Invest, 105(8):1057-1065, 2000.
  29. Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen.
    Shibata, MA et al. Carcinogenesis, 19(1):195-205, 1998.

    30.  

    Chemoprevention / Therapy

  30. Distinct Tumor Stage-Specific Inhibitory Effects of 2-Methoxyestradiol in a Breast Cancer Mouse Model Associated with Reduced Id-1 Expression.
    Huh, J-I. et al. Cancer Research, in press, 2006.
  31. MIS Suppresses Tumor Growth in the C3(1)T Antigen Transgenic Mouse Mammary Carcinoma Model.
    Gupta, V. et al. Proc. Natl. Acad. Sci. (USA), 102(9):3219-24, 2005.
  32. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through anti-angiogenic and non-antiangiogenic mechanisms.
    Huh, J-I. et al. Oncogene, 24(5):790-800, 2005.
  33. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
    Moody, T.W. et al. Life Sci. 74, 1345-1357, 2004.
  34. Comparative effects of lovastatin on murine mammary and prostate cancers in a transgenic mouse model.
    Shibata, M-A et al. Carcinogenesis, Mar;24(3):453-459, 2003.
  35. Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice.
    Calvo, A et al. Cancer Research, 62:3934-3938, 2002.
  36. Inhibition of the mammary gland adenocarcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.
    Calvo, A et al. Int. J. Oncology, 101(3):224-234, 2002.
  37. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
    Yang, YA et al. J.Clin.Invest, 109(12):1607-1615, 2002.
  38. Suppression of mammary tumorigenesis in transgenic mice by the RXR- selective retinoid, LGD1069.
    Wu, K et al. Cancer Epidemiol.Biomarkers Prev., 11(5):467-474, 2002.
  39. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model.
    Yokoyama, Y et al. Cancer Res., 60(16):4362-4365, 2000.
  40. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
    Shibata, MA et al. Cancer Gene Ther., 8(1):23-35, 2001.
  41. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
    Green, JE et al. Cancer Res., 61(20):7449-7455, 2001.
  42. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
    Wigginton, JM et al. J.Immunol., 166(2):1156-1168, 2001.
  43. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.
    Wu, K et al. Clin.Cancer Res., 6(9):3696-3704, 2000.

    44.  

    Molecular and Cellular Biology

  44. Identification of a novel non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.
    Utomo, A. et al. J Biol Chem., 279(42):43522-9, 200.
  45. Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions.
    Kaczmarczyk, SJ et al. Nucleic Acids Res.31:e86, 2003.
  46. Molecular profiling of angiogenesis markers.
    Shih, S-C. et al. American Journal of Pathology, 161(1):35-41, 2002.
  47. A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression.
    Kaczmarczyk, SJ et al. Nucleic Acids Res., 29(12):E56-E56, 2001.
  48. Use of the survivin promoter to activate cancer specific gene expression.
    Bao, R. et al. JNCI, 94(7):522-8, 2002.
  49. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells.
    Guo, C et al. J.Biol.Chem., 276(8):5992-5999, 2001.
  50. Ventral prostate predominant l, a novel mouse gene expressed exclusively in the prostate.
    Wubah, JA et al. Prostate, 51(1):21-29, 2002.
  51. Differential targeting of protein kinase CK2 to the nuclear matrix upon transient overexpression of its subunits.
    Yu, S et al. J.Cell Biochem., 74(1):127-134, 1999.

    52.  

    Reviews

  52. The promise of genetically engineered mice for cancer prevention studies.
    Green, J.E. and Hudson, T. Nature Reviews Cancer, 5(3):184-198, 2005.
  53. Interrogating Mouse Mammary Cancer Models: insights from gene expression profiling.
    Fargiano, A.A. et al. Journal of Mammary Gland Biology and Neoplasia, 8(3):321-34, 2003.
  54. Molecular mechanisms of breast cancer progression: lessons from mouse mammary cancer models and gene expression profiling.
    Ye, Y. et al. Breast Disease, 19:69-82, 2004.
  55. Chipping Away at Breast Cancer: insights from microarray studies of human and mouse mammary cancer.
    Desai, K.V. et al. Endocrine Related Cancer, Dec;9(4):207-20, 2002.
  56. Pre-clinical applications of transgenic mouse mammary cancer models.
    Kavanaugh, C. et al. Transgenic Research, 11(6):617-33, 2002.
  57. Loss of estrogen receptor alpha and its contribution to tumorigenesis in breast cancer.
    Couldrey, C. et. al. Cancer Research Alert, 2: (12), 133-137, 2001.
  58. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.
    Cardiff, RD et al. Oncogene, 19(8):968-988, 2000.
  59. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
    Green, JE et al. Oncogene, 19(8):1020-1027, 2000.